Ivosidenib is a treatment for specific types of acute myeloid leukemia, and its price, dosage and precautions are the focus of attention of patients and medical workers. The purpose of this article is to comprehensively review this information to help patients better understand and use Ivosidenib.

The price of Ivosidenib

The price of Ivosidenib varies depending on the brand, specification and purchase channel.

Price details

At present, on the market, the Laos Lucius brand of Ivosidenib has a specification of 250mg*60 tablets; The price of the Everest brand of Ivosidenib in Bangladesh is for reference only.

Reason for the price difference

The main reasons for the price difference of Ivosidenib include brand, production cost, marketing strategy and purchase channel. Different brands of drugs may have differences in production processes, raw material procurement, quality control, etc., which will affect the cost. In addition, market supply and demand, regional differences, and differences in sales channels can also lead to price fluctuations.

When patients buy Ivosidenib, they should first ascertain the authenticity of the drug. It is recommended to purchase through regular hospitals, online pharmacies or formal medical service institutions, and avoid purchasing through informal channels. At the same time, patients can consult a doctor or pharmacist to understand the price difference of different brands and specifications, and make a choice based on their own economic situation.

Dosage of Ivosidenib

Proper dosing and dosing of Ivosidenib is key to determining its efficacy and safety.

Dosage

According to clinical guidelines, the recommended dose of Ivosidenib is 500mg orally once daily. Patients should follow the doctor's instructions and take the medication on time and in the right amount. At the same time, it is necessary to pay attention to some details during the process of taking the drug to determine the best absorption and utilization of the drug. Reasonable dosage can not only improve the therapeutic effect, but also reduce the occurrence of adverse reactions.

When and how to take the drug

Ivosidenib can be taken orally on an empty stomach or after meals, but should be avoided with high-fat meals to avoid affecting drug absorption. It is recommended to take the drug at the same time every day to form a stable blood concentration. If vomiting occurs after taking the medicine, there is no need to make up the dose; If you miss a dose or do not take the medication at the scheduled time, you should take it as soon as possible, but if it is less than 12 hours before the next dose, you do not need to take it again.

During the course of treatment, the doctor will adjust the dose of Ivosidenib according to the patient's specific situation and adverse reactions. At the same time, patients need to undergo regular blood counts, blood biochemistry, and electrocardiogram (ECG) tests to monitor drug efficacy and possible toxicity. Any abnormal findings should be addressed promptly to determine the safety and efficacy of treatment.

Precautions for the use of Ivosidenib

During the use of Ivosidenib, patients should be especially aware of the potential risks of differentiation syndrome, QTc prolongation, Guillain-Barré syndrome, and hypokalemia. These adverse reactions may endanger the life of patients and must be taken seriously.

Prevention of differentiation syndrome

Differentiation syndrome is one of the serious adverse effects that may occur during treatment with Ivosidenib. Patients should pay close attention to whether they have symptoms such as noninfectious leukocytosis, peripheral edema, and fever. As soon as symptoms are suspected, you should seek medical attention and receive appropriate treatment.

Monitoring for QTc interval prolongation

Ivosidenib may cause a prolonged QTc interval and increase the risk of ventricular arrhythmias. Therefore, patients should monitor ECGs and electrolyte levels regularly during treatment. Patients at risk for QTc prolongation, such as those with congenital long QTc syndrome, should be monitored more frequently.

In addition to the above two points, patients should also be aware of Guillain-Barré syndrome and hypokalemia. With comprehensive medication guidance and monitoring, patients can use Ivosidenib more safely for optimal treatment outcomes.